<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK220444" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK220444/" /><meta name="ncbi_pagename" content="Dihydrolipoamide Dehydrogenase Deficiency - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Dihydrolipoamide Dehydrogenase Deficiency - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Dihydrolipoamide Dehydrogenase Deficiency" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2014/07/17" /><meta name="citation_author" content="Shane C Quinonez" /><meta name="citation_author" content="Jess G Thoene" /><meta name="citation_pmid" content="25032271" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK220444/" /><meta name="citation_keywords" content="DLD Deficiency" /><meta name="citation_keywords" content="E3 Deficiency" /><meta name="citation_keywords" content="Lipoamide Dehydrogenase Deficiency" /><meta name="citation_keywords" content="DLD Deficiency" /><meta name="citation_keywords" content="E3 Deficiency" /><meta name="citation_keywords" content="Lipoamide Dehydrogenase Deficiency" /><meta name="citation_keywords" content="Dihydrolipoyl dehydrogenase, mitochondrial" /><meta name="citation_keywords" content="DLD" /><meta name="citation_keywords" content="Dihydrolipoamide Dehydrogenase Deficiency" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Dihydrolipoamide Dehydrogenase Deficiency" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Shane C Quinonez" /><meta name="DC.Contributor" content="Jess G Thoene" /><meta name="DC.Date" content="2014/07/17" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK220444/" /><meta name="description" content="The phenotypes of dihydrolipoamide dehydrogenase (DLD) deficiency are an overlapping continuum that ranges from early-onset neurologic manifestations to adult-onset isolated liver involvement. Early-onset DLD deficiency typically manifests as a hypotonic infant with lactic acidosis. Affected infants frequently do not survive their initial metabolic decompensation, or die within the first few years of life during a recurrent metabolic decompensation. Children who live beyond the first two to three years frequently exhibit growth deficiencies and residual neurologic deficits (intellectual disability, spasticity, ataxia, and seizures). In contrast, isolated liver involvement can present as early as the neonatal period and as late as the third decade. Evidence of liver injury/failure is preceded by nausea and emesis and frequently associated with encephalopathy and/or coagulopathy. Acute metabolic episodes are frequently associated with lactate elevations, hyperammonemia, and hepatomegaly. With resolution of the acute episodes patients frequently return to baseline with no residual neurologic deficit or intellectual disability. Liver failure can result in death, even in those with late-onset disease." /><meta name="og:title" content="Dihydrolipoamide Dehydrogenase Deficiency" /><meta name="og:type" content="book" /><meta name="og:description" content="The phenotypes of dihydrolipoamide dehydrogenase (DLD) deficiency are an overlapping continuum that ranges from early-onset neurologic manifestations to adult-onset isolated liver involvement. Early-onset DLD deficiency typically manifests as a hypotonic infant with lactic acidosis. Affected infants frequently do not survive their initial metabolic decompensation, or die within the first few years of life during a recurrent metabolic decompensation. Children who live beyond the first two to three years frequently exhibit growth deficiencies and residual neurologic deficits (intellectual disability, spasticity, ataxia, and seizures). In contrast, isolated liver involvement can present as early as the neonatal period and as late as the third decade. Evidence of liver injury/failure is preceded by nausea and emesis and frequently associated with encephalopathy and/or coagulopathy. Acute metabolic episodes are frequently associated with lactate elevations, hyperammonemia, and hepatomegaly. With resolution of the acute episodes patients frequently return to baseline with no residual neurologic deficit or intellectual disability. Liver failure can result in death, even in those with late-onset disease." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK220444/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/dld-def/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK220444/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C0629E04065F10000000006AA025E.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK220444_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK220444_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/diastrophic-d/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/dcm-ov/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK220444_"><span class="title" itemprop="name">Dihydrolipoamide Dehydrogenase Deficiency</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: DLD Deficiency, E3 Deficiency, Lipoamide Dehydrogenase Deficiency</div><p class="contrib-group"><span itemprop="author">Shane C Quinonez</span>, MD and <span itemprop="author">Jess G Thoene</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK220444_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK220444_ai__"><div class="contrib half_rhythm"><span itemprop="author">Shane C Quinonez</span>, MD<div class="affiliation small">Clinical Lecturer <br />University of Michigan<br />Ann Arbor, Michigan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.hcimu.dem@noniuqs" class="oemail">ude.hcimu.dem@noniuqs</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Jess G Thoene</span>, MD<div class="affiliation small">Active Emeritus Professor of Pediatrics<br />Director, Biochemical Genetics Laboratory<br />University of Michigan<br />Ann Arbor, Michigan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.hcimu.dem@eneohtj" class="oemail">ude.hcimu.dem@eneohtj</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">July 17, 2014</span>.</p><p><em>Estimated reading time: 24 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="dld-def.Summary" itemprop="description"><h2 id="_dld-def_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>The phenotypes of dihydrolipoamide dehydrogenase (DLD) deficiency are an overlapping continuum that ranges from early-onset neurologic manifestations to adult-onset <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> liver involvement. Early-onset DLD deficiency typically manifests as a hypotonic infant with lactic acidosis. Affected infants frequently do not survive their initial metabolic decompensation, or die within the first few years of life during a recurrent metabolic decompensation. Children who live beyond the first two to three years frequently exhibit growth deficiencies and residual neurologic deficits (intellectual disability, spasticity, ataxia, and seizures). In contrast, isolated liver involvement can present as early as the neonatal period and as late as the third decade. Evidence of liver injury/failure is preceded by nausea and emesis and frequently associated with encephalopathy and/or coagulopathy. Acute metabolic episodes are frequently associated with lactate elevations, hyperammonemia, and hepatomegaly. With resolution of the acute episodes patients frequently return to baseline with no residual neurologic deficit or intellectual disability. Liver failure can result in death, even in those with late-onset disease.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of DLD deficiency is suspected in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a characteristic clinical history and biochemical evidence of defective function of three mitochondrial enzyme complexes (branched chain alpha-ketoacid dehydrogenase [BCKDH] complex, &#x003b1;-ketoglutarate dehydrogenase [&#x003b1;KGDH] complex, and pyruvate dehydrogenase [PDH] complex). These may manifest as lactic acidosis, elevated &#x003b1;-ketoglutarate in the urine, the presence of branched chain keto-acids in the urine, elevated plasma levels of branched chain amino acids (leucine, isoleucine, and valine), and the presence of allo-isoleucine in plasma. Of note, these biochemical changes may be absent or intermittent. The diagnosis is confirmed by the presence of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>DLD</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Management of DLD deficiency is difficult due to the various metabolic pathways involved. Management of the early-onset neurologic presentation relies on empiric treatment of the three <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> enzyme complex deficiencies (none of which appear to significantly alter the natural history of the disease):</p><ul><li class="half_rhythm"><div>BCKDH complex deficiency: dietary leucine restriction, BCAA-free medical foods, judicious supplementation with isoleucine and valine, and frequent clinical and biochemical monitoring;</div></li><li class="half_rhythm"><div>&#x003b1;KGDH complex: very rare, no recommendations available;</div></li><li class="half_rhythm"><div>PDH complex: ketogenic diet (due to defective carbohydrate oxidation), trial of dichloroacetate (DCA), and thiamine supplementation.</div></li></ul><p>Management of the primarily hepatic presentation typically involves supportive therapy during times of acute liver injury or failure, including nutritional support, IV glucose for hypoglycemia, correction of metabolic acidosis, correction of coagulopathy, and avoidance of liver-toxic medications.</p><p><i>Prevention of primary manifestations:</i> No compelling evidence exists for the prevention of acute episodes, despite multiple attempted dietary strategies and medications.</p><p><i>Surveillance:</i> Routine monitoring of growth and development; plasma amino acid levels (to guide dietary management). For those receiving DCA, monitoring for the development of peripheral neuropathy.</p><p><i>Agents/circumstances to avoid:</i> Fasting, catabolic stressors, liver-toxic medications.</p><p><i>Evaluation of relatives at risk:</i> If the <i>DLD</i> pathogenic variants in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are known, at-risk sibs should undergo <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> prenatally or as soon as possible after birth so that those who have inherited both pathogenic variants can receive appropriate interventions and avoid risk factors that may precipitate an acute event.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>DLD deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <i>DLD</i> pathogenic variants in the family are known.</p></div></div><div id="dld-def.Diagnosis"><h2 id="_dld-def_Diagnosis_">Diagnosis</h2><p>Dihydrolipoamide dehydrogenase (DLD) functions as the E3 subunit of three mitochondrial enzyme complexes: branched chain alpha-ketoacid dehydrogenase (BCKDH) complex, &#x003b1;-ketoglutarate dehydrogenase (&#x003b1;KGDH) complex, and pyruvate dehydrogenase (PDH) complex [<a class="bk_pop" href="#dld-def.REF.chuang.2014">Chuang et al 2014</a>]. Of note, although DLD also functions as the L protein of the glycine cleavage system, pathogenic variants of <i>DLD</i> do not appear to date to impair the function of this system in vivo.</p><p>The phenotypic spectrum of DLD deficiency includes an early-onset neurologic presentation, a primarily hepatic presentation, and a mild myopathic presentation (seen in one patient).</p><p>No formal diagnostic criteria have been established for dihydrolipoamide dehydrogenase (DLD) deficiency.</p><p><b>The diagnosis of dihydrolipoamide dehydrogenase (DLD) deficiency is suspected in individuals with the following presentations:</b></p><ul><li class="half_rhythm"><div>Neurologic (early-onset hypotonia, lethargy, and emesis)</div><ul><li class="half_rhythm"><div>In untreated infants, manifestations progress to deepening encephalopathy (lethargy, tone abnormalities, feeding difficulties, decreased level of alertness, and occasionally seizures) and eventual death.</div></li><li class="half_rhythm"><div>Those who survive the first years of life frequently display neurologic impairment.</div></li><li class="half_rhythm"><div>Abnormal laboratory findings typically associated with the neurologic presentation include the following:</div><ul><li class="half_rhythm"><div>Metabolic acidosis. Arterial pH &#x0003c;7.35 or venous pH &#x0003c;7.32 and serum bicarbonate &#x0003c;22 mmol/L in children and adults or &#x0003c;17 mmol/L in neonates</div></li><li class="half_rhythm"><div>Elevated plasma concentration of lactate: &#x0003e;2.2 mmol/L</div></li><li class="half_rhythm"><div>Hypoglycemia: &#x0003c;40 mg/dL (&#x0003c;2.2 mmol/L)</div></li></ul></li></ul></li><li class="half_rhythm"><div>Hepatic (recurrent liver injury/failure frequently preceded by nausea and emesis)</div><ul><li class="half_rhythm"><div>Liver injury can range from <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> elevated transaminases to fulminant hepatic failure and death.</div></li><li class="half_rhythm"><div>Age of onset ranges from the neonatal period to the third decade [<a class="bk_pop" href="#dld-def.REF.barak.1998.482">Barak et al 1998</a>, <a class="bk_pop" href="#dld-def.REF.brassier.2013.28">Brassier et al 2013</a>].</div></li><li class="half_rhythm"><div>Patients with the hepatic form typically have normal intellect with no residual neurologic deficit between acute metabolic episodes unless neurologic damage has occurred.</div></li></ul></li><li class="half_rhythm"><div>Myopathic. The one patient with this mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> exhibited ptosis, weakness, and elevated plasma creatine kinase and lactate levels [<a class="bk_pop" href="#dld-def.REF.quintana.2010.s315">Quintana et al 2010</a>].</div></li><li class="half_rhythm"><div>Elevated citrulline on <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> (NBS) dried blood spot. Two symptomatic infants with DLD deficiency had an elevated citrulline level on dried blood spot testing [<a class="bk_pop" href="#dld-def.REF.haviv.2014.243">Haviv et al 2014</a>]. Note that newborn screening has failed to identify asymptomatic individuals with DLD deficiency when either dried blood spot citrulline or leucine is used as a primary screening <a class="def" href="/books/n/gene/glossary/def-item/analyte/">analyte</a>.</div></li></ul><p><b>The diagnosis of dihydrolipoamide dehydrogenase deficiency is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the following:</b></p><ul><li class="half_rhythm"><div>A clinical history consistent with DLD deficiency (see preceding section)</div></li><li class="half_rhythm"><div>Biochemical evidence of defective BCKDH, &#x003b1;KGDH, or PDH function:</div><ul><li class="half_rhythm"><div class="half_rhythm">Lactic acidosis (plasma lactate &#x0003e;2.2 mmol/L and arterial pH &#x0003c;7.35)</div></li><li class="half_rhythm"><div class="half_rhythm">Elevated urine &#x003b1;-ketoglutarate levels (see <a class="figpopup" href="/books/NBK220444/table/dld-def.T.metabolic_abnormalities_in_dld/?report=objectonly" target="object" rid-figpopup="figdlddefTmetabolicabnormalitiesindld" rid-ob="figobdlddefTmetabolicabnormalitiesindld">Table 1</a>)</div></li><li class="half_rhythm"><div class="half_rhythm">Presence of branched chain keto-acids in urine</div></li><li class="half_rhythm"><div class="half_rhythm">Elevated branched chain amino acids (leucine, isoleucine, and valine) in plasma and the presence of allo-isoleucine in plasma (see <a class="figpopup" href="/books/NBK220444/table/dld-def.T.metabolic_abnormalities_in_dld/?report=objectonly" target="object" rid-figpopup="figdlddefTmetabolicabnormalitiesindld" rid-ob="figobdlddefTmetabolicabnormalitiesindld">Table 1</a>)</div><div class="half_rhythm">Note: Individuals with an early-onset or hepatic presentation only occasionally have biochemical evidence of dysfunctional branched chain amino acid (BCAA) metabolism (i.e., elevations of allo-isoleucine and branched chain ketoacids; see <a class="figpopup" href="/books/NBK220444/table/dld-def.T.metabolic_abnormalities_in_dld/?report=objectonly" target="object" rid-figpopup="figdlddefTmetabolicabnormalitiesindld" rid-ob="figobdlddefTmetabolicabnormalitiesindld">Table 1</a>), making leucine an unreliable marker for screening.</div></li></ul></li><li class="half_rhythm"><div>The presence of either <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>DLD</i> (see <a class="figpopup" href="/books/NBK220444/table/dld-def.T.summary_of_molecular_genetic_t/?report=objectonly" target="object" rid-figpopup="figdlddefTsummaryofmoleculargenetict" rid-ob="figobdlddefTsummaryofmoleculargenetict">Table 2</a>) or decreased DLD enzymatic activity in fibroblasts, lymphocytes, or liver tissue if <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is not available or is not definitive</div></li></ul><div id="dld-def.T.metabolic_abnormalities_in_dld" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Metabolic Abnormalities in DLD Deficiency by Presentation</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK220444/table/dld-def.T.metabolic_abnormalities_in_dld/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dld-def.T.metabolic_abnormalities_in_dld_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_1" style="text-align:left;vertical-align:middle;">Metabolite</th><th id="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Presentation</th><th id="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_3" style="text-align:left;vertical-align:middle;">Normal</th></tr><tr><th headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2" id="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Neurologic</th><th headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2" id="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hepatic</th></tr></thead><tbody><tr><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Plasma lactate</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Elevated</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Elevated</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;2.2 &#x000b5;mol/L</td></tr><tr><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urine &#x003b1;-ketoglutarate&#x000a0;<sup>1</sup></td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal to elevated</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically normal</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neonates: 4-524 mmol/mol creatinine<br />Children: 36-117 mmol/mol creatinine<br />Adults: 4-74 mmol/mol creatinine</td></tr><tr><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urine branched chain keto-acids&#x000a0;<sup>1</sup></td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent to elevated</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically absent</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neonates&#x000a0;<sup>2</sup>: &#x0003c;7 mmol/mol creatinine<br />All other ages: not detectable</td></tr><tr><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plasma leucine&#x000a0;<sup>3</sup></td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal to elevated</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically normal</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infants: 46-147 &#x000b5;mol/L<br />Children: 30-246 &#x000b5;mol/L<br />Adolescents-adults: 86-206 &#x000b5;mol/L</td></tr><tr><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plasma isoleucine&#x000a0;<sup>3</sup></td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal to elevated</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically normal</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infants: 12-77 &#x000b5;mol/L<br />Children: 6-122 &#x000b5;mol/L<br />Adolescents-adults: 34-106 &#x000b5;mol</td></tr><tr><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plasma valine&#x000a0;<sup>3</sup></td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal to elevated</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically normal</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infants: 79-217 &#x000b5;mol/L<br />Children: 132-480 &#x000b5;mol/L<br />Adolescents-adults: 155-343 &#x000b5;mol</td></tr><tr><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plasma allo-isoleucine</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal to elevated</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_2 hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically normal</td><td headers="hd_h_dld-def.T.metabolic_abnormalities_in_dld_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;5 &#x000b5;mol/L&#x000a0;<sup>4</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="dld-def.TF.1.1"><p class="no_margin"><a class="bk_pop" href="#dld-def.REF.hoffmann.2002">Hoffmann &#x00026; Feyh [2002]</a></p></div></dd><dt>2. </dt><dd><div id="dld-def.TF.1.2"><p class="no_margin">2-oxoisocaproate and 2-oxo-3-methylvalerate; 2-oxoisovalerate detectable only in premature infants</p></div></dd><dt>3. </dt><dd><div id="dld-def.TF.1.3"><p class="no_margin"><a class="bk_pop" href="#dld-def.REF.shih.2002">Shih [2002]</a></p></div></dd><dt>4. </dt><dd><div id="dld-def.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#dld-def.REF.schadewaldt.1999.1734">Schadewaldt et al [1999]</a></p></div></dd></dl></div></div></div><div id="dld-def.T.summary_of_molecular_genetic_t" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Summary of Molecular Genetic Testing Used in Dihydrolipoamide Dehydrogenase Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK220444/table/dld-def.T.summary_of_molecular_genetic_t/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dld-def.T.summary_of_molecular_genetic_t_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_dld-def.T.summary_of_molecular_genetic_t_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_dld-def.T.summary_of_molecular_genetic_t_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_dld-def.T.summary_of_molecular_genetic_t_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_dld-def.T.summary_of_molecular_genetic_t_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>DLD</i></td><td headers="hd_h_dld-def.T.summary_of_molecular_genetic_t_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>2</sup></td><td headers="hd_h_dld-def.T.summary_of_molecular_genetic_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">39/40 (98%)&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_dld-def.T.summary_of_molecular_genetic_t_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_dld-def.T.summary_of_molecular_genetic_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_dld-def.T.summary_of_molecular_genetic_t_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>6</sup></td><td headers="hd_h_dld-def.T.summary_of_molecular_genetic_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 7</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="dld-def.TF.2.1"><p class="no_margin">See <a href="/books/NBK220444/#dld-def.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein. See <a href="#dld-def.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>2. </dt><dd><div id="dld-def.TF.2.2"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>3. </dt><dd><div id="dld-def.TF.2.3"><p class="no_margin"><a class="bk_pop" href="#dld-def.REF.liu.1993.5186">Liu et al [1993]</a>, <a class="bk_pop" href="#dld-def.REF.hong.1996.1925">Hong et al [1996]</a>, <a class="bk_pop" href="#dld-def.REF.hong.1997.160">Hong et al [1997]</a>, <a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al [1999]</a>, <a class="bk_pop" href="#dld-def.REF.shany.1999.163">Shany et al [1999]</a>, <a class="bk_pop" href="#dld-def.REF.cerna.2001.1319">Cerna et al [2001]</a>, <a class="bk_pop" href="#dld-def.REF.grafakou.2003.714">Grafakou et al [2003]</a>, <a class="bk_pop" href="#dld-def.REF.hong.2003.816">Hong et al [2003]</a>, <a class="bk_pop" href="#dld-def.REF.odi_vre.2005.323">Odi&#x000e8;vre et al [2005]</a>, <a class="bk_pop" href="#dld-def.REF.cameron.2006.1542">Cameron et al [2006]</a>, <a class="bk_pop" href="#dld-def.REF.sansaricq.2006.203">Sansaricq et al [2006]</a>, <a class="bk_pop" href="#dld-def.REF.quintana.2010.s315">Quintana et al [2010]</a>, <a class="bk_pop" href="#dld-def.REF.brassier.2013.28">Brassier et al [2013]</a>, <a class="bk_pop" href="#dld-def.REF.quinonez.2013.67">Quinonez et al [2013]</a>, <a class="bk_pop" href="#dld-def.REF.haviv.2014.243">Haviv et al [2014]</a></p></div></dd><dt>4. </dt><dd><div id="dld-def.TF.2.4"><p class="no_margin">Testing that identifies <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications not detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Included in the variety of methods that may be used are: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this gene/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>5. </dt><dd><div id="dld-def.TF.2.5"><p class="no_margin">No deletions or duplications involving <i>DLD</i> have been reported to cause dihydrolipoamide dehydrogenase deficiency.</p></div></dd><dt>6. </dt><dd><div id="dld-def.TF.2.6"><p class="no_margin">Variant panels may differ by laboratory.</p></div></dd><dt>7. </dt><dd><div id="dld-def.TF.2.7"><p class="no_margin">The <a class="figpopup" href="/books/NBK220444/table/dld-def.T.dld_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figdlddefTdldpathogenicvariantsdiscus" rid-ob="figobdlddefTdldpathogenicvariantsdiscus">c.685G&#x0003e;T</a> (p.Gly229Cys) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is common in Ashkenazi Jews (see <a href="#dld-def.Prevalence">Prevalence</a>).</p></div></dd></dl></div></div></div></div><div id="dld-def.Clinical_Characteristics"><h2 id="_dld-def_Clinical_Characteristics_">Clinical Characteristics</h2><div id="dld-def.Clinical_Description"><h3>Clinical Description</h3><p>As part of three mitochondrial enzyme complexes (branched chain alpha-ketoacid dehydrogenase complex, &#x003b1;-ketoglutarate dehydrogenase complex, and pyruvate dehydrogenase complex), dihydrolipoamide dehydrogenase (DLD) functions as the E3 subunit responsible for the reoxidation of the reduced lipoyl moiety of the E2 subunit.</p><p>Persons with dihydrolipoamide dehydrogenase (DLD) deficiency exhibit variable phenotypic and biochemical consequences based on the three affected enzyme complexes. Although the spectrum of disease ranges from early-onset neurologic manifestations to <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> adult-onset liver involvement, it is a continuum and differentiation between the two major presentations can occasionally be difficult.</p><p><b>Early-onset neurologic presentation.</b> The most frequent clinical picture in early-onset DLD deficiency is that of a hypotonic infant with lactic acidosis (<a class="figpopup" href="/books/NBK220444/table/dld-def.T.features_of_the_earlyonset_neu/?report=objectonly" target="object" rid-figpopup="figdlddefTfeaturesoftheearlyonsetneu" rid-ob="figobdlddefTfeaturesoftheearlyonsetneu">Table 3</a>). Affected infants frequently do not survive their initial metabolic decompensation or die within the first one to two years of life during a recurrent metabolic decompensation. Children who live beyond the first two to three years frequently exhibit growth deficiencies and residual neurologic deficits including intellectual disability, spasticity (hypertonia and/or hyperreflexia), ataxia, and seizures. Of note, normal intellectual functioning has been reported in individuals with early-onset disease with compound heterozygosity for the <a class="figpopup" href="/books/NBK220444/table/dld-def.T.dld_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figdlddefTdldpathogenicvariantsdiscus" rid-ob="figobdlddefTdldpathogenicvariantsdiscus">c.685G&#x0003e;T</a> (p.Gly229Cys) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and an additional pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al 1999</a>].</p><p>Hepatomegaly and liver dysfunction/failure (elevated transaminases, synthetic failure) occur in individuals with an early-onset neurologic picture and can occasionally be a cause of death (<a class="figpopup" href="/books/NBK220444/table/dld-def.T.features_of_the_earlyonset_neu/?report=objectonly" target="object" rid-figpopup="figdlddefTfeaturesoftheearlyonsetneu" rid-ob="figobdlddefTfeaturesoftheearlyonsetneu">Table 3</a>).</p><p>Similar to other inborn errors of metabolism, DLD deficiency is associated with recurrent episodes of metabolic decompensation typically triggered by illness/fever, surgery, fasting, or diet (high in fats and/or protein). Owing to the variability in each individual&#x02019;s biochemical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, some patients have experienced worsening of clinical status with high-fat diets [<a class="bk_pop" href="#dld-def.REF.robinson.1981.35">Robinson et al 1981</a>, <a class="bk_pop" href="#dld-def.REF.hong.1997.160">Hong et al 1997</a>, <a class="bk_pop" href="#dld-def.REF.brassier.2013.28">Brassier et al 2013</a>], while others have achieved metabolic control with ketogenic diets (see <a href="#dld-def.Management">Management</a>) [<a class="bk_pop" href="#dld-def.REF.cerna.2001.1319">Cerna et al 2001</a>, <a class="bk_pop" href="#dld-def.REF.grafakou.2003.714">Grafakou et al 2003</a>].</p><p>Liver biopsies have shown increased glycogen content and mild fibrosis or fatty, acute necrosis with a Reye syndrome-like appearance [<a class="bk_pop" href="#dld-def.REF.grafakou.2003.714">Grafakou et al 2003</a>, <a class="bk_pop" href="#dld-def.REF.cameron.2006.1542">Cameron et al 2006</a>]. Between acute episodes both liver size and transaminase levels can return to normal [<a class="bk_pop" href="#dld-def.REF.sansaricq.2006.203">Sansaricq et al 2006</a>].</p><p>Other findings of the early-onset neurologic presentation include the following:</p><ul><li class="half_rhythm"><div><b>Leigh syndrome <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></b>, identified in at least six patients with DLD deficiency [<a class="bk_pop" href="#dld-def.REF.quinonez.2013.67">Quinonez et al 2013</a>]</div></li><li class="half_rhythm"><div><b>Cardiac dysfunction,</b> reported with hypertrophic cardiomyopathy in two patients and &#x0201c;myocardial dysfunction&#x0201d; in one [<a class="bk_pop" href="#dld-def.REF.shany.1999.163">Shany et al 1999</a>, <a class="bk_pop" href="#dld-def.REF.odi_vre.2005.323">Odi&#x000e8;vre et al 2005</a>, <a class="bk_pop" href="#dld-def.REF.cameron.2006.1542">Cameron et al 2006</a>]</div></li><li class="half_rhythm"><div><b>Hyperammonemia</b> (&#x02264;250 &#x000b5;mol/L), observed at the time of initial presentation although typically associated with various degrees of hepatic injury/failure [<a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al 1999</a>, <a class="bk_pop" href="#dld-def.REF.quinonez.2013.67">Quinonez et al 2013</a>]</div></li><li class="half_rhythm"><div><b>Vision impairment/optic atrophy</b> [<a class="bk_pop" href="#dld-def.REF.robinson.1977.1198">Robinson et al 1977</a>, <a class="bk_pop" href="#dld-def.REF.hong.1997.160">Hong et al 1997</a>, <a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al 1999</a>, <a class="bk_pop" href="#dld-def.REF.shany.1999.163">Shany et al 1999</a>]</div></li></ul><div id="dld-def.T.features_of_the_earlyonset_neu" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Features of the Early-Onset Neurologic Phenotype</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK220444/table/dld-def.T.features_of_the_earlyonset_neu/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dld-def.T.features_of_the_earlyonset_neu_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:top;">Disease Features</th><th id="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Frequency&#x000a0;<sup>1</sup></th><th id="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">%</th></tr></thead><tbody><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" rowspan="13" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Clinical presentation&#x000a0;<sup>2</sup></b></td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hypotonia</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Developmental delay</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Emesis</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Hepatomegaly</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Lethargy</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Seizures</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Spasticity (hypertonia and/or hyperreflexia)</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Leigh syndrome <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Failure to thrive</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Microcephaly</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Vision impairment</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Ataxia</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Cardiac involvement</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" rowspan="11" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Laboratory abnormalities</b></td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Metabolic acidosis&#x000a0;<sup>3</sup></td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">91</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Elevated plasma lactate&#x000a0;<sup>4</sup></td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Elevated urine &#x003b1;-ketoglutarate&#x000a0;<sup>4</sup></td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Hypoglycemia&#x000a0;<sup>5</sup></td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Elevated plasma BCAA&#x000a0;<sup>4</sup></td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Elevated transaminases</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Elevated urine branched chain keto-acids&#x000a0;<sup>4</sup></td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Hepatic failure</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Elevated plasma allo-isoleucine&#x000a0;<sup>4</sup></td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Low free plasma carnitine&#x000a0;<sup>6</sup></td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13</td></tr><tr><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Hyperammonemia&#x000a0;<sup>7</sup></td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2/23</td><td headers="hd_h_dld-def.T.features_of_the_earlyonset_neu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Only patients biochemically confirmed to have DLD deficiency included</p></div></dd><dt></dt><dd><div><p class="no_margin">BCAA = branched chain amino acids</p></div></dd><dt>1. </dt><dd><div id="dld-def.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#dld-def.REF.robinson.1977.1198">Robinson et al [1977]</a>, <a class="bk_pop" href="#dld-def.REF.robinson.1981.35">Robinson et al [1981]</a>, <a class="bk_pop" href="#dld-def.REF.munnich.1982.167">Munnich et al [1982]</a>, <a class="bk_pop" href="#dld-def.REF.kuhara.1983.133">Kuhara et al [1983]</a>, <a class="bk_pop" href="#dld-def.REF.matalon.1984.65">Matalon et al [1984]</a>, <a class="bk_pop" href="#dld-def.REF.bonnefont.1992.255">Bonnefont et al [1992]</a>, <a class="bk_pop" href="#dld-def.REF.liu.1993.5186">Liu et al [1993]</a>, <a class="bk_pop" href="#dld-def.REF.elpeleg.1995.72">Elpeleg et al [1995]</a>, <a class="bk_pop" href="#dld-def.REF.craigen.1996.69">Craigen [1996]</a>, <a class="bk_pop" href="#dld-def.REF.hong.1996.1925">Hong et al [1996]</a>, <a class="bk_pop" href="#dld-def.REF.elpeleg.1997b.256">Elpeleg et al [1997b]</a>, <a class="bk_pop" href="#dld-def.REF.hong.1997.160">Hong et al [1997]</a>, <a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al [1999]</a>, <a class="bk_pop" href="#dld-def.REF.shany.1999.163">Shany et al [1999]</a>, <a class="bk_pop" href="#dld-def.REF.cerna.2001.1319">Cerna et al [2001]</a>, <a class="bk_pop" href="#dld-def.REF.grafakou.2003.714">Grafakou et al [2003]</a>, <a class="bk_pop" href="#dld-def.REF.hong.2003.816">Hong et al [2003]</a>, <a class="bk_pop" href="#dld-def.REF.odi_vre.2005.323">Odi&#x000e8;vre et al [2005]</a>, <a class="bk_pop" href="#dld-def.REF.cameron.2006.1542">Cameron et al [2006]</a>, <a class="bk_pop" href="#dld-def.REF.sansaricq.2006.203">Sansaricq et al [2006]</a>, <a class="bk_pop" href="#dld-def.REF.quinonez.2013.67">Quinonez et al [2013]</a></p></div></dd><dt>2. </dt><dd><div id="dld-def.TF.3.2"><p class="no_margin">Later physical examination and neurologic findings are likely underrepresented as children with an early-onset presentation frequently die in their first year(s) of life.</p></div></dd><dt>3. </dt><dd><div id="dld-def.TF.3.3"><p class="no_margin">Arterial pH &#x0003c;7.35 or venous pH &#x0003c;7.32; serum bicarbonate &#x0003c;22 mmol/L in infants, children, and adults; or &#x0003c;17 mmol/L in neonates</p></div></dd><dt>4. </dt><dd><div id="dld-def.TF.3.4"><p class="no_margin">See <a class="figpopup" href="/books/NBK220444/table/dld-def.T.metabolic_abnormalities_in_dld/?report=objectonly" target="object" rid-figpopup="figdlddefTmetabolicabnormalitiesindld" rid-ob="figobdlddefTmetabolicabnormalitiesindld">Table 1</a>.</p></div></dd><dt>5. </dt><dd><div id="dld-def.TF.3.5"><p class="no_margin">Glucose &#x0003c;40 mg/dL</p></div></dd><dt>6. </dt><dd><div id="dld-def.TF.3.6"><p class="no_margin">Carnitine (free) &#x0003c;38&#x000b1;22 [<a class="bk_pop" href="#dld-def.REF.millington.2002">Millington 2002</a>]</p></div></dd><dt>7. </dt><dd><div id="dld-def.TF.3.7"><p class="no_margin">Ammonia &#x0003e;100 &#x000b5;mol/L in neonates or &#x0003e;60 &#x000b5;mol/L in infants, children, and adults</p></div></dd></dl></div></div></div><p><b>Hepatic presentation.</b> Patients with a primarily hepatic presentation can develop signs and symptoms as early as the neonatal period and as late as the third decade of life [<a class="bk_pop" href="#dld-def.REF.barak.1998.482">Barak et al 1998</a>, <a class="bk_pop" href="#dld-def.REF.brassier.2013.28">Brassier et al 2013</a>]. Evidence of liver injury/failure (<a class="figpopup" href="/books/NBK220444/table/dld-def.T.clinical_features_of_the_hepat/?report=objectonly" target="object" rid-figpopup="figdlddefTclinicalfeaturesofthehepat" rid-ob="figobdlddefTclinicalfeaturesofthehepat">Table 4</a>) is preceded by nausea and emesis and frequently associated with encephalopathy and/or coagulopathy. Liver failure as a cause of death has been reported in multiple patients, including those who presented later in life [<a class="bk_pop" href="#dld-def.REF.elpeleg.1997a.238">Elpeleg et al 1997a</a>, <a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al 1999</a>].</p><p>Acute metabolic episodes are frequently associated with lactate elevations, hyperammonemia, and hepatomegaly. With resolution of the acute episodes (see <a href="#dld-def.Management">Management</a>) patients may return to baseline with normal transaminases, coagulation parameters, mental status, and no residual neurologic deficit or intellectual disability.</p><p>Affected individuals frequently experience lifelong recurrent attacks of hepatopathy that decrease with age. Attacks are often precipitated by catabolism, intercurrent illness/fever, and dietary extremes. These patients additionally are more susceptible to hepatotropic viruses (e.g., Epstein-Barr virus) and medications (e.g., acetaminophen) [<a class="bk_pop" href="#dld-def.REF.brassier.2013.28">Brassier et al 2013</a>, <a class="bk_pop" href="#dld-def.REF.quinonez.2013.67">Quinonez et al 2013</a>].</p><p>Liver biopsy electron microscopy has shown the presence of lipid droplets [<a class="bk_pop" href="#dld-def.REF.brassier.2013.28">Brassier et al 2013</a>].</p><div id="dld-def.T.clinical_features_of_the_hepat" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Clinical Features of the Hepatic Phenotype</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK220444/table/dld-def.T.clinical_features_of_the_hepat/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dld-def.T.clinical_features_of_the_hepat_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Disease Features</th><th id="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency&#x000a0;<sup>1</sup></th><th id="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">%</th></tr></thead><tbody><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" rowspan="6" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Clinical presentation</b></td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nausea/emesis</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Hepatomegaly</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">69</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Hepatic encephalopathy</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">54</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Muscle cramps</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Behavioral disturbances</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Vision loss</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" rowspan="8" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Laboratory abnormalities</b></td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated transaminases</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Coagulopathy</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">85</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Elevated lactate&#x000a0;<sup>2</sup></td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">77</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Hyperammonemia&#x000a0;<sup>3</sup></td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">62</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Hypoglycemia&#x000a0;<sup>4</sup></td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">38</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Elevated urine &#x003b1;-ketoglutarate&#x000a0;<sup>2</sup></td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Low carnitine&#x000a0;<sup>5</sup></td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8</td></tr><tr><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Elevated plasma BCAA&#x000a0;<sup>2</sup></td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/13</td><td headers="hd_h_dld-def.T.clinical_features_of_the_hepat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Only patients biochemically confirmed to have DLD deficiency included</p></div></dd><dt></dt><dd><div><p class="no_margin">BCAA = branched chain amino acids</p></div></dd><dt>1. </dt><dd><div id="dld-def.TF.4.1"><p class="no_margin"><a class="bk_pop" href="#dld-def.REF.elpeleg.1990.709">Elpeleg et al [1990]</a>, <a class="bk_pop" href="#dld-def.REF.aptowitzer.1997.599">Aptowitzer et al [1997]</a>, <a class="bk_pop" href="#dld-def.REF.elpeleg.1997a.238">Elpeleg et al [1997a]</a>, <a class="bk_pop" href="#dld-def.REF.barak.1998.482">Barak et al [1998]</a>, <a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al [1999]</a>, <a class="bk_pop" href="#dld-def.REF.brassier.2013.28">Brassier et al [2013]</a></p></div></dd><dt>2. </dt><dd><div id="dld-def.TF.4.2"><p class="no_margin">See <a class="figpopup" href="/books/NBK220444/table/dld-def.T.metabolic_abnormalities_in_dld/?report=objectonly" target="object" rid-figpopup="figdlddefTmetabolicabnormalitiesindld" rid-ob="figobdlddefTmetabolicabnormalitiesindld">Table 1</a>.</p></div></dd><dt>3. </dt><dd><div id="dld-def.TF.4.3"><p class="no_margin">Ammonia &#x0003e;100 &#x000b5;mol/L in neonates or &#x0003e;60 &#x000b5;mol/L in infants, children, and adults</p></div></dd><dt>4. </dt><dd><div id="dld-def.TF.4.4"><p class="no_margin">Glucose &#x0003c;40 mg/dL</p></div></dd><dt>5. </dt><dd><div id="dld-def.TF.4.5"><p class="no_margin">Carnitine (free) &#x0003c;38&#x000b1;22 [<a class="bk_pop" href="#dld-def.REF.millington.2002">Millington 2002</a>]</p></div></dd></dl></div></div></div><p>Although <a class="figpopup" href="/books/NBK220444/table/dld-def.T.features_of_the_earlyonset_neu/?report=objectonly" target="object" rid-figpopup="figdlddefTfeaturesoftheearlyonsetneu" rid-ob="figobdlddefTfeaturesoftheearlyonsetneu">Table 3</a> and <a class="figpopup" href="/books/NBK220444/table/dld-def.T.clinical_features_of_the_hepat/?report=objectonly" target="object" rid-figpopup="figdlddefTclinicalfeaturesofthehepat" rid-ob="figobdlddefTclinicalfeaturesofthehepat">Table 4</a> reveal features common to both the early-onset neurologic presentation and the hepatic presentation (i.e., elevated transaminases, hepatomegaly, and lactate elevations), differentiation of the two types can be difficult especially in neonates [<a class="bk_pop" href="#dld-def.REF.hong.2003.816">Hong et al 2003</a>, <a class="bk_pop" href="#dld-def.REF.cameron.2006.1542">Cameron et al 2006</a>]. To date, the only patient with a hepatic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> who displayed hypotonia or residual neurologic deficiencies had experienced a severe episode associated with deep coma and residual vision loss and behavioral disturbances [<a class="bk_pop" href="#dld-def.REF.elpeleg.1990.709">Elpeleg et al 1990</a>]. Therefore, the absence of hypotonia and neurologic deficit and the presence of hepatic signs are useful discriminating features.</p><p><b>Myopathic presentation.</b> One patient has been described with a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> consisting primarily of myopathic symptoms [<a class="bk_pop" href="#dld-def.REF.quintana.2010.s315">Quintana et al 2010</a>]. The patient exhibited ptosis, weakness, and an elevated creatine kinase and lactate.</p></div><div id="dld-def.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Phenotypic severity is difficult to predict based on <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> and residual enzyme function [<a class="bk_pop" href="#dld-def.REF.shany.1999.163">Shany et al 1999</a>, <a class="bk_pop" href="#dld-def.REF.quinonez.2013.67">Quinonez et al 2013</a>].</p><p>Individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <a class="figpopup" href="/books/NBK220444/table/dld-def.T.dld_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figdlddefTdldpathogenicvariantsdiscus" rid-ob="figobdlddefTdldpathogenicvariantsdiscus">c.685G&#x0003e;T</a> (p.Gly229Cys) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, which is common in the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> population, were initially thought to have a milder, primarily hepatic presentation. Subsequently, individuals homozygous for <a class="figpopup" href="/books/NBK220444/table/dld-def.T.dld_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figdlddefTdldpathogenicvariantsdiscus" rid-ob="figobdlddefTdldpathogenicvariantsdiscus">c.685G&#x0003e;T</a> (p.Gly229Cys) were found to have the early-onset neonatal neurologic presentation as well [<a class="bk_pop" href="#dld-def.REF.hong.2003.816">Hong et al 2003</a>, <a class="bk_pop" href="#dld-def.REF.sansaricq.2006.203">Sansaricq et al 2006</a>]. Conversely, all individuals with an exclusively hepatic presentation have been homozygous for the <a class="figpopup" href="/books/NBK220444/table/dld-def.T.dld_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figdlddefTdldpathogenicvariantsdiscus" rid-ob="figobdlddefTdldpathogenicvariantsdiscus">c.685G&#x0003e;T</a> (p.Gly229Cys) pathogenic variant [<a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al 1999</a>, <a class="bk_pop" href="#dld-def.REF.brassier.2013.28">Brassier et al 2013</a>].</p><p>Newborn screening (NBS) has recently identified two symptomatic infants with DLD deficiency who had an elevated citrulline level on dried blood spot (DBS) testing [<a class="bk_pop" href="#dld-def.REF.haviv.2014.243">Haviv et al 2014</a>]. Both of these infants as well as all subsequently identified children in the initial report were <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <a class="figpopup" href="/books/NBK220444/table/dld-def.T.dld_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figdlddefTdldpathogenicvariantsdiscus" rid-ob="figobdlddefTdldpathogenicvariantsdiscus">c.685G&#x0003e;T</a> (p.Gly229Cys) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for that <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and another pathogenic variant. An elevated citrulline level has also been seen in a patient without the <a class="figpopup" href="/books/NBK220444/table/dld-def.T.dld_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figdlddefTdldpathogenicvariantsdiscus" rid-ob="figobdlddefTdldpathogenicvariantsdiscus">c.685G&#x0003e;T</a> (p.Gly229Cys) allele [Authors, personal observation]. Note: The exact mechanism of hypercitrullinemia in these infants has yet to be identified; aspartate depletion through decreased oxaloacetate production has been suggested [<a class="bk_pop" href="#dld-def.REF.haviv.2014.243">Haviv et al 2014</a>].</p></div><div id="dld-def.Nomenclature"><h3>Nomenclature</h3><p>DLD deficiency is occasionally referred to as maple syrup urine disease (MSUD) type 3 as it functions as the E3 subunit of BCKDH. Note that MSUD type 1 is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>BCKDHA</i> (E1&#x003b1;) or <i>BCKDHB</i> (E1&#x003b2;) and MSUD type 2 is caused by biallelic pathogenic variants in <i>DBT</i> (E2). See <a href="/books/n/gene/msud/">Maple Syrup Urine Disease</a>.</p></div><div id="dld-def.Prevalence"><h3>Prevalence</h3><p>In the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> population, the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of the <a class="figpopup" href="/books/NBK220444/table/dld-def.T.dld_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figdlddefTdldpathogenicvariantsdiscus" rid-ob="figobdlddefTdldpathogenicvariantsdiscus">c.685G&#x0003e;T</a> (p.Gly229Cys) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is estimated to be between 1:94 and 1:110 with an estimated disease frequency of 1:35,000 to 1:48,000 [<a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al 1999</a>, <a class="bk_pop" href="#dld-def.REF.scott.2010.1240">Scott et al 2010</a>]. This is likely an underestimate of disease, as additional pathogenic variants account for DLD deficiency in this population as well [<a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al 1999</a>].</p><p>The incidence and <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency in other populations is unknown and likely very rare.</p></div></div><div id="dld-def.Genetically_Related_Allelic_Diso"><h2 id="_dld-def_Genetically_Related_Allelic_Diso_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>DLD</i>.</p></div><div id="dld-def.Differential_Diagnosis"><h2 id="_dld-def_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Pyruvate dehydrogenase complex (PDHC) deficiency</b> most commonly presents with neurologic impairment, hypotonia, structural brain abnormalities, and lactic acidosis with a normal lactate:pyruvate ratio [<a class="bk_pop" href="#dld-def.REF.patel.2012.385">Patel et al 2012</a>]. While the clinical findings and preliminary laboratory values are similar, individuals with DLD deficiency frequently also display biochemical evidence of: (a) defective &#x003b1;-ketoglutarate dehydrogenase with elevated urine &#x003b1;-ketoglutarate; and (b) branched chain alpha-ketoacid dehydrogenase complex dysfunction with elevated plasma branched chain amino acids and urine branched chain ketoacids.</p><p><a href="/books/n/gene/msud/"><b>Maple syrup urine disease (MSUD) types 1 and 2</b></a><b>.</b> Signs in individuals with classic MSUD by age:</p><ul><li class="half_rhythm"><div><b>12 to 24 hours.</b> A maple syrup odor in cerumen, elevated plasma concentrations of branched-chain amino acids (BCAAs) (leucine, isoleucine, and valine) and allo-isoleucine, and a generalized disturbance of plasma amino acid concentration ratios</div></li><li class="half_rhythm"><div><b>Two to three days.</b> Ketonuria, irritability, and poor feeding</div></li><li class="half_rhythm"><div><b>Four to five days.</b> Deepening encephalopathy manifesting as lethargy, intermittent apnea, opisthotonus, and stereotyped movements such as "fencing" and "bicycling"</div></li><li class="half_rhythm"><div><b>Seven to ten days.</b> Possible coma and central respiratory failure</div></li></ul><p>Individuals with DLD deficiency (which may be referred to as MSUD type 3; see <a href="#dld-def.Nomenclature">Nomenclature</a>) can typically be differentiated from MSUD types 1 and 2 by the presence of severe lactic acidosis, &#x003b1;-ketoglutarate excretion in the urine, and liver involvement. The maple syrup odor frequently seen in patients with MSUD types 1 and 2 is not typically found in individuals with DLD deficiency.</p><p><b>Isolated &#x003b1;-ketoglutarate dehydrogenase deficiency</b> has been reported in two sets of <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> siblings with choreoathetoid movements, hypotonia, developmental delay, and lactic acidosis. All patients exhibited <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> elevations of &#x003b1;-ketoglutarate in the urine [<a class="bk_pop" href="#dld-def.REF.kohlsch_tter.1982.32">Kohlsch&#x000fc;tter et al 1982</a>, <a class="bk_pop" href="#dld-def.REF.guffon.1993.821">Guffon et al 1993</a>].</p><p><b>Elevated citrulline on <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> dried blood spot</b> has been identified in two symptomatic patients with DLD deficiency [<a class="bk_pop" href="#dld-def.REF.haviv.2014.243">Haviv et al 2014</a>]. As recommended by the American College of Medical Genetics (see <a href="http://www.acmg.net/PDFLibrary/Citrullinemia.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ACMG ACT Sheet</a> / <a href="https://www.acmg.net/docs/ACT%20Sheets/Algorithms/Visio-Citrulline.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ACMG Algorithm</a>), other causes of an elevated citrulline on dried blood spot including <a href="/books/n/gene/ctlm/">citrullinemia type I</a>, <a href="/books/n/gene/args-aciduria/">argininosuccinic acidemia</a>, <a href="/books/n/gene/citrin/">citrullinemia type II</a> (citrin deficiency), and <a href="/books/n/gene/pdc/">pyruvate carboxylase deficiency</a> should be investigated.</p><p><b>Defects in lipoic acid metabolism</b> have recently been identified as a cause of neonatal lactic acidosis and a biochemical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> similar to DLD deficiency. Lipoic acid is the essential cofactor attached to the E2 subunits of BCKDH, &#x003b1;KGDH, and PDH as well as to the H protein of the glycine cleavage system (see <a href="/books/n/gene/nkh/">Glycine Encephalopathy</a>). Pathogenic variants have been identified in multiple genes encoding enzymes involved in lipoic acid metabolism: <i>NUF1</i>, <i>BOLA3</i>, <i>LIAS</i>, <i>IBA57</i>, and <i>LIPT1</i> [<a class="bk_pop" href="#dld-def.REF.cameron.2011.486">Cameron et al 2011</a>, <a class="bk_pop" href="#dld-def.REF.mayr.2011.792">Mayr et al 2011</a>, <a class="bk_pop" href="#dld-def.REF.navarrosastre.2011.656">Navarro-Sastre et al 2011</a>, <a class="bk_pop" href="#dld-def.REF.ajit_bolar.2013.2590">Ajit Bolar et al 2013</a>, <a class="bk_pop" href="#dld-def.REF.haack.2013.55">Haack et al 2013</a>, <a class="bk_pop" href="#dld-def.REF.soreze.2013.192">Soreze et al 2013</a>, <a class="bk_pop" href="#dld-def.REF.tort.2014.1907">Tort et al 2014</a>]. Unlike children with DLD deficiency, children with defects in lipoic acid metabolism (except <i>LIPT1</i> deficiency) have elevated glycine in body fluids.</p></div><div id="dld-def.Management"><h2 id="_dld-def_Management_">Management</h2><div id="dld-def.Evaluations_Following_Initial_Di"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with dihydrolipoamide dehydrogenase (DLD) deficiency, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>In the acute setting, measurement/evaluation of:</div><ul><li class="half_rhythm"><div>Blood acid-base status</div></li><li class="half_rhythm"><div>Plasma/serum concentration of lactate, glucose, and ammonia</div></li><li class="half_rhythm"><div>Plasma amino acids</div></li><li class="half_rhythm"><div>Plasma total and free carnitine</div></li><li class="half_rhythm"><div>Urine organic acids</div></li><li class="half_rhythm"><div>Liver function and transaminases (ALT/AST)</div></li><li class="half_rhythm"><div>Liver size via physical examination and/or ultrasonography</div></li><li class="half_rhythm"><div>Cardiac size via echocardiography</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></li><li class="half_rhythm"><div>After metabolic stability has been achieved:</div><ul><li class="half_rhythm"><div>Clinical assessment of physical growth and development status</div></li><li class="half_rhythm"><div>Formal ophthalmologic evaluation if concern for vision loss</div></li><li class="half_rhythm"><div>Brain MRI if clinical concern for Leigh-like syndrome or other structural brain damage</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></li></ul></div><div id="dld-def.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Consensus recommendations for the management of DLD deficiency do not currently exist. Theoretical difficulties exist for the management of these patients based on the various metabolic pathways <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by the three affected enzyme complexes. In practice, these difficulties have been experienced and make empiric treatment recommendations challenging.</p><p><i>DLD</i> pathogenic variants cause variable deficiency in three enzymatic pathways. The treatment for individual enzyme complex deficiencies warrants consideration:</p><ul><li class="half_rhythm"><div><b>Branched chain &#x003b1;-ketoacid dehydrogenase (BCKDH) complex.</b> Management consists primarily of dietary leucine restriction, BCAA-free medical foods, judicious supplementation with isoleucine and valine, and frequent clinical and biochemical monitoring (see <a href="/books/n/gene/msud/">MSUD</a>).</div></li><li class="half_rhythm"><div><b>Alpha-ketoglutarate dehydrogenase (&#x003b1;KGDH) complex.</b> Due to the rarity of this <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> deficiency, limited information is available for the management of these patients.</div></li><li class="half_rhythm"><div><b>Pyruvate dehydrogenase (PDH) complex.</b> Due to defective carbohydrate oxidation, ketogenic diets have become part of regular management in these patients. Additionally, dichloroacetate (DCA) and thiamine supplementation are frequently tried [<a class="bk_pop" href="#dld-def.REF.patel.2012.385">Patel et al 2012</a>].</div></li></ul><div id="dld-def.EarlyOnset_Neurologic_Presentati"><h4>Early-Onset Neurologic Presentation</h4><p><b>Review of treatment strategies.</b> The multiple strategies that have been attempted in children with an early-onset neurologic presentation do not appear to significantly alter the natural history of disease. Even with treatment, children often die in the neonatal/infantile period or experience various degrees of chronic neurologic impairment if they survive the initial episode. The individual treatment strategies typically address deficiency of one abnormal enzymatic complex.</p><p><b>Protein/BCAA-restriction.</b> Based on decreased BCKDH activity, restriction of protein to recommended dietary allowances (RDA) has been attempted with questionable results. Three of the six reported patients experienced laboratory and/or clinical improvement with the use of protein restriction alone or in combination with medication therapy [<a class="bk_pop" href="#dld-def.REF.craigen.1996.69">Craigen 1996</a>, <a class="bk_pop" href="#dld-def.REF.elpeleg.1997b.256">Elpeleg et al 1997b</a>, <a class="bk_pop" href="#dld-def.REF.grafakou.2003.714">Grafakou et al 2003</a>].</p><p><b>Ketogenic/high-fat diet.</b> Ketogenic/high-fat diets are frequently employed in PDH deficiency [<a class="bk_pop" href="#dld-def.REF.patel.2012.385">Patel et al 2012</a>] and as a result have been attempted in DLD deficiency. A total of seven patients reported to date have been tried on a ketogenic/high-fat diet:</p><ul><li class="half_rhythm"><div>Five had no clinical or biochemical benefit. Of note, two of the five experienced clinical worsening with an increase in acidosis and hypoglycemia [<a class="bk_pop" href="#dld-def.REF.robinson.1981.35">Robinson et al 1981</a>, <a class="bk_pop" href="#dld-def.REF.craigen.1996.69">Craigen 1996</a>].</div></li><li class="half_rhythm"><div>Two improved clinically. One was treated with lipid infusions (instead of high-dextrose infusions) during acute episodes [<a class="bk_pop" href="#dld-def.REF.hong.1997.160">Hong et al 1997</a>, <a class="bk_pop" href="#dld-def.REF.cerna.2001.1319">Cerna et al 2001</a>].</div></li></ul><p><b>Carbohydrate tolerance.</b> Patients with PDH deficiency classically present with lactate elevations due to defective carbohydrate oxidation. Although dextrose infusions may theoretically cause further lactate elevations during acute episodes, provision of dextrose-containing IV fluids is essential for the majority of acutely decompensated patients. Only one patient experienced worsening acidosis with increased dextrose concentrations in the TPN [<a class="bk_pop" href="#dld-def.REF.cerna.2001.1319">Cerna et al 2001</a>]. Not surprisingly, this patient is one of the two who benefitted from a ketogenic/high-fat diet.</p><p><b>Dichloroacetate (DCA).</b> Through its ability to stimulate PDH activity by inhibiting PDH kinase, DCA has long been used to safely treat patients with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> lactic acidosis, mitochondrial disorders, and PDH deficiency [<a class="bk_pop" href="#dld-def.REF.stacpoole.2008.e1223">Stacpoole et al 2008</a>, <a class="bk_pop" href="#dld-def.REF.patel.2012.385">Patel et al 2012</a>]. A total of five patients have been tried on DCA with four experiencing at least transient decreases in lactic acid elevations [<a class="bk_pop" href="#dld-def.REF.craigen.1996.69">Craigen 1996</a>, <a class="bk_pop" href="#dld-def.REF.elpeleg.1997b.256">Elpeleg et al 1997b</a>, <a class="bk_pop" href="#dld-def.REF.cerna.2001.1319">Cerna et al 2001</a>].</p><p>Additional therapies used with limited success include:</p><ul><li class="half_rhythm"><div>Thiamine</div></li><li class="half_rhythm"><div>Coenzyme Q<sub>10</sub></div></li><li class="half_rhythm"><div>Lipoic acid</div></li><li class="half_rhythm"><div>Riboflavin</div></li><li class="half_rhythm"><div>Biotin</div></li></ul><p><b>Empiric recommendations</b>
<b>for acute management</b> (based on the above review)</p><p>Goals of therapy should be the correction of metabolic acidosis, promotion of an anabolic/metabolically stable state, maintenance of normoglycemia, and treatment of precipitating factors that may be present. This is typically achieved by the following:</p><ul><li class="half_rhythm"><div>Metabolic acidosis should be treated with sodium bicarbonate if bicarbonate is &#x02264;14 mEq/L and/or blood pH &#x0003c;7.2.</div></li><li class="half_rhythm"><div>Promotion of an anabolic state:</div><ul><li class="half_rhythm"><div>Maintain serum glucose concentration in the normal range. D<sub>10</sub> (half or full-normal saline) with age-appropriate electrolytes should be started at maintenance rate and adjusted based on the presence or absence of increased intracranial pressure or hypoglycemia.</div><ul><li class="half_rhythm"><div>Elevation of plasma leucine and increased intracranial pressure are a potential complication of DLD deficiency. Similar to the management of classic MSUD link, overhydration and quickly infused boluses of fluids should be avoided if possible.</div></li><li class="half_rhythm"><div>If provision of dextrose-containing fluids worsens metabolic acidosis, consider decreasing the infusion rate and providing the majority of calories in the form of intralipid.</div></li></ul></li><li class="half_rhythm"><div>Intralipids can be added to provide additional calories with cautious monitoring for acidemia.</div></li></ul></li><li class="half_rhythm"><div>Protein should initially be withheld for a maximum of 24 hours to avoid worsening of catabolism. Protein should then be reintroduced gradually.</div><ul><li class="half_rhythm"><div>Branched-chain amino acids should be introduced slowly and followed closely with frequent plasma amino acid evaluations.</div></li><li class="half_rhythm"><div>Goal levels/ratios should be similar to those listed in <a href="/books/n/gene/msud/">MSUD</a>.</div></li></ul></li><li class="half_rhythm"><div>Levocarnitine (IV or PO) 50 - 100 mg/kg/d divided three times per day should be given during the acute period.</div></li><li class="half_rhythm"><div>Dichloroacetate (DCA) can be considered and continued if lactate decreases with its introduction.</div></li><li class="half_rhythm"><div>Any precipitating factors (infection, fasting, medications) should be treated/discontinued as soon as possible.</div></li><li class="half_rhythm"><div>If lactic acidosis/encephalopathy persists, dialysis can be considered as it has been successful in DLD deficiency and classic MSUD [<a class="bk_pop" href="#dld-def.REF.schaefer.1999.910">Schaefer et al 1999</a>, <a class="bk_pop" href="#dld-def.REF.quinonez.2013.67">Quinonez et al 2013</a>].</div></li></ul></div><div id="dld-def.Hepatic_Presentation"><h4>Hepatic Presentation</h4><p>Management of patients with the primarily hepatic presentation typically involves supportive therapy during times of acute liver injury or failure, including the following:</p><ul><li class="half_rhythm"><div>Nutritional support in the form of dextrose-containing IV fluids (6-8 mg/kg/min) with age-appropriate electrolytes and/or frequent feedings [<a class="bk_pop" href="#dld-def.REF.elpeleg.1990.709">Elpeleg et al 1990</a>, <a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al 1999</a>, <a class="bk_pop" href="#dld-def.REF.brassier.2013.28">Brassier et al 2013</a>]</div></li><li class="half_rhythm"><div>Correction of metabolic acidosis with sodium bicarbonate</div></li><li class="half_rhythm"><div>Correction of any coagulopathy with fresh frozen plasma</div></li><li class="half_rhythm"><div>Consideration of DCA treatment for lactic acidosis during acute episodes and for chronic management [<a class="bk_pop" href="#dld-def.REF.aptowitzer.1997.599">Aptowitzer et al 1997</a>, <a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al 1999</a>]</div></li><li class="half_rhythm"><div>Use of dialysis to treat persistent lactic acidosis and encephalopathy (successfully in 1 patient) [<a class="bk_pop" href="#dld-def.REF.elpeleg.1990.709">Elpeleg et al 1990</a>]</div></li><li class="half_rhythm"><div>Avoidance of liver-toxic medications</div></li></ul><p>Episodes of catabolic stress (e.g., intercurrent illness, surgical procedures, pregnancy) require the assistance/care of a biochemical geneticist.</p><p>Limited data exist for chronic management of individuals with the primarily hepatic presentation. Between episodes, patients typically return to baseline and do not require treatment beyond the avoidance of fasting, catabolic stressors, and liver-toxic medications.</p></div></div><div id="dld-def.Prevention_of_Primary_Manifestat"><h3>Prevention of Primary Manifestations</h3><p>No compelling evidence exists for the prevention of acute episodes, despite multiple attempted dietary strategies and medications. The frequency of acute episodes decreases with age in most patients with DLD deficiency.</p><p>Although no specific therapy exists to prevent the neurologic dysfunction and/or the hepatic manifestations of DLD deficiency, avoidance of precipitating factors is recommended. As such, empiric recommendations include the following:</p><ul><li class="half_rhythm"><div>Provide protein intake at or around RDA and titrate based on growth and plasma amino acid values. See <a href="/books/n/gene/msud/">MSUD</a> for the recommended intake and target levels of leucine, isoleucine, and valine.</div></li><li class="half_rhythm"><div>Supplement with levocarnitine if deficient.</div></li><li class="half_rhythm"><div>Avoid fasting, catabolic states, and extremes of dietary intake until dietary tolerance/stressors are identified.</div></li><li class="half_rhythm"><div>Avoid liver-toxic medications.</div></li></ul></div><div id="dld-def.Prevention_of_Secondary_Complica"><h3>Prevention of Secondary Complications</h3><p>Age-appropriate immunizations including the influenza vaccine should be provided.</p><p>Dichloroacetate (DCA) has been associated with the development of peripheral neuropathy; thus, patients receiving this medication require close monitoring [<a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al 1999</a>, <a class="bk_pop" href="#dld-def.REF.stacpoole.2008.e1223">Stacpoole et al 2008</a>].</p></div><div id="dld-def.Surveillance"><h3>Surveillance</h3><p>A patient&#x02019;s primary care physician and biochemical geneticist should follow growth and development regularly. Developmental delays should be identified and treated as early as possible.</p><p>Plasma amino acid levels should be regularly followed to guide dietary management by the biochemical geneticist in conjunction with a qualified metabolic nutritionist.</p><p>Complications of DLD deficiency including hepatomegaly, cardiomyopathy, and CNS changes require regular surveillance if present.</p><p>Patients receiving dichloroacetate (DCA) need to be monitored for the development of peripheral neuropathy [<a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al 1999</a>, <a class="bk_pop" href="#dld-def.REF.stacpoole.2008.e1223">Stacpoole et al 2008</a>].</p></div><div id="dld-def.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>Fasting</div></li><li class="half_rhythm"><div>Catabolic stressors</div></li><li class="half_rhythm"><div>Liver-toxic medications</div></li></ul></div><div id="dld-def.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>If the <i>DLD</i> pathogenic variants in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> relative are known, at-risk sibs should undergo <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> as soon as possible after birth so that those who have inherited both pathogenic variants can receive appropriate treatment and avoid risk factors that may precipitate an acute event. In some instances, families choose to perform prenatal testing so that treatment can begin shortly after birth for those who have inherited both pathogenic variants.</p><p>See <a href="#dld-def.Related_Genetic_Counseling_Issue">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="dld-def.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="dld-def.Genetic_Counseling"><h2 id="_dld-def_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="dld-def.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Dihydrolipoamide dehydrogenase (DLD) deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="dld-def.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the risk of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with DLD deficiency are obligate heterozygotes (carriers) for a <i>DLD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>&#x02019;s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="dld-def.Carrier_Detection"><h3>Carrier Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>DLD</i> pathogenic variants in the family.</p></div><div id="dld-def.Related_Genetic_Counseling_Issue"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#dld-def.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="dld-def.Prenatal_Testing_and_Preimplanta"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once both <i>DLD</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and preimplantion genetic diagnosis for DLD deficiency are possible.</p></div></div><div id="dld-def.Resources"><h2 id="_dld-def_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition/pyruvate-dehydrogenase-deficiency" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Pyruvate Dehydrogenase Deficiency</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li><li class="half_rhythm"><div><b>United Mitochondrial Disease Foundation (UMDF)</b></div><div>8085 Saltsburg Road</div><div>Suite 201</div><div>Pittsburg PA 15239</div><div><b>Phone:</b> 888-317-8633 (toll-free); 412-793-8077</div><div><b>Fax:</b> 412-793-6477</div><div><b>Email:</b> info@umdf.org</div><div><a href="http://www.umdf.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.umdf.org</a></div></li><li class="half_rhythm"><div><b>RDCRN Patient Contact Registry: North American Mitochondrial Disease Consortium</b></div><div><a href="https://www.rarediseasesnetwork.org/cms/namdc" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Patient Contact Registry</a></div></li></ul></div><div id="dld-def.Molecular_Genetics"><h2 id="_dld-def_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="dld-def.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Dihydrolipoamide Dehydrogenase Deficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK220444/table/dld-def.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dld-def.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_dld-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_dld-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_dld-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_dld-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_dld-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_dld-def.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_dld-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1738" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>DLD</i></a></td><td headers="hd_b_dld-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1738" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">7q31<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_dld-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P09622" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Dihydrolipoyl dehydrogenase, mitochondrial</a></td><td headers="hd_b_dld-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/DLD" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DLD database</a></td><td headers="hd_b_dld-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=DLD" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DLD</a></td><td headers="hd_b_dld-def.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=DLD[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DLD</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="dld-def.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="dld-def.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Dihydrolipoamide Dehydrogenase Deficiency (<a href="/omim/238331,246900" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK220444/table/dld-def.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dld-def.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/238331" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">238331</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DIHYDROLIPOAMIDE DEHYDROGENASE; DLD</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/246900" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">246900</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none found</td></tr></tbody></table></div></div><div id="dld-def.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>Dihydrolipoamide dehydrogenase (DLD) functions as the E3 subunit in three mitochondrial enzyme complexes (BCKDH, &#x003b1;KGDH, PDH) and the L protein of the glycine cleavage system.</p><p>As the E3 subunit, it catalyzes the oxidative regeneration of the lipoic acid covalently bound to the E2 subunit, generating NADH in the process. <i>DLD</i> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> pathogenic variants lead to variable dysfunction of BCKDH, &#x003b1;KGDH, and PDH. The decreased activity of these three enzyme complexes leads to the often severe and variable <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> seen in DLD deficiency.</p><p>To date no patient with DLD deficiency has presented with biochemical evidence of glycine cleavage system dysfunction (see <a href="/books/n/gene/nkh/">Glycine Encephalopathy</a>).</p><p>Additionally, multiple <i>DLD</i> pathogenic variants have been associated with elevated reactive oxygen species (ROS) generation [<a class="bk_pop" href="#dld-def.REF.vaubel.2011.40232">Vaubel et al 2011</a>, <a class="bk_pop" href="#dld-def.REF.ambrus.2013.145">Ambrus &#x00026; Adam-Vizi 2013</a>].</p><p><b>Gene structure.</b>
<i>DLD</i> comprises 14 exons and is approximately 30 kb long. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK220444/#dld-def.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Variant types include <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, small deletions, small insertions, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants [<a class="bk_pop" href="#dld-def.REF.quinonez.2013.67">Quinonez et al 2013</a>].</p><p>The <a class="figpopup" href="/books/NBK220444/table/dld-def.T.dld_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="figdlddefTdldpathogenicvariantsdiscus" rid-ob="figobdlddefTdldpathogenicvariantsdiscus">c.685G&#x0003e;T</a> (p.Gly229Cys) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is common in the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> population. Carrier frequency is estimated at between 1:94 and 1:110 [<a class="bk_pop" href="#dld-def.REF.shaag.1999.177">Shaag et al 1999</a>, <a class="bk_pop" href="#dld-def.REF.scott.2010.1240">Scott et al 2010</a>].</p><div id="dld-def.T.dld_pathogenic_variants_discus" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p><i>DLD</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK220444/table/dld-def.T.dld_pathogenic_variants_discus/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__dld-def.T.dld_pathogenic_variants_discus_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_dld-def.T.dld_pathogenic_variants_discus_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_dld-def.T.dld_pathogenic_variants_discus_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_dld-def.T.dld_pathogenic_variants_discus_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_dld-def.T.dld_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.685G&#x0003e;T&#x000a0;<sup>1</sup></td><td headers="hd_h_dld-def.T.dld_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly229Cys</td><td headers="hd_h_dld-def.T.dld_pathogenic_variants_discus_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000108.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000108<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_000099.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000099<wbr style="display:inline-block"></wbr>​.2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="dld-def.TF.5.1"><p class="no_margin">See <a href="#dld-def.Prevalence">Prevalence</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The normal gene product is dihydrolipoamide dehydrogenase, a 50-kd protein composed of 509 amino acids.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants cause the dihydrolipoamide dehydrogenase enzyme to be inactive or absent.</p></div></div><div id="dld-def.References"><h2 id="_dld-def_References_">References</h2><div id="dld-def.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.ajit_bolar.2013.2590">Ajit Bolar N, Vanlander AV, Wilbrecht C, Van der Aa N, Smet J, De Paepe B, Vandeweyer G, Kooy F, Eyskens F, De Latter E, Delanghe G, Govaert P, Leroy JG, Loeys B, Lill R, Van Laer L, Van Coster R. Mutation of the iron-sulfur cluster assembly gene IBA57 causes severe myopathy and encephalopathy. <span><span class="ref-journal">Hum Mol Genet. </span>2013;<span class="ref-vol">22</span>:2590–602.</span> [<a href="/pubmed/23462291" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23462291</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.ambrus.2013.145">Ambrus A, Adam-Vizi V. Molecular dynamics study of the structural basis of dysfunction and the modulation of reactive oxygen species generation by pathogenic mutants of human dihydrolipoamide dehydrogenase. <span><span class="ref-journal">Arch Biochem Biophys. </span>2013;<span class="ref-vol">538</span>:145–55.</span> [<a href="/pubmed/24012808" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24012808</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.aptowitzer.1997.599">Aptowitzer I, Saada A, Faber J, Kleid D, Elpeleg ON. Liver disease in the Ashkenazi-Jewish lipoamide dehydrogenase deficiency. <span><span class="ref-journal">J Pediatr Gastroenterol Nutr. </span>1997;<span class="ref-vol">24</span>:599–601.</span> [<a href="/pubmed/9161958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9161958</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.barak.1998.482">Barak N, Huminer D, Segal T, Ben Ari Z, Halevy J, Tur-Kaspa R. Lipoamide dehydrogenase deficiency: a newly discovered cause of acute hepatitis in adults. <span><span class="ref-journal">J Hepatol. </span>1998;<span class="ref-vol">29</span>:482–4.</span> [<a href="/pubmed/9764998" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9764998</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.bonnefont.1992.255">Bonnefont JP, Chretien D, Rustin P, Robinson B, Vassault A, Aupetit J, Charpentier C, Rabier D, Saudubray JM, Munnich A. Alpha-ketoglutarate dehydrogenase deficiency presenting as congenital lactic acidosis. <span><span class="ref-journal">J Pediatr. </span>1992;<span class="ref-vol">121</span>:255–8.</span> [<a href="/pubmed/1640293" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1640293</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.brassier.2013.28">Brassier A, Ottolenghi C, Boutron A, Bertrand AM, Valmary-Degano S, Cervoni JP, Chretien D, Arnoux JB, Rabier D, Lacaille F, de Keyzer Y, Di Martino V, de Lonlay P. Dihydrolipoamide dehydrogenase deficiency: a still overlooked cause of recurrent acute liver failure and Reye-like syndrome. <span><span class="ref-journal">Mol Genet Metab. </span>2013;<span class="ref-vol">109</span>:28–32.</span> [<a href="/pubmed/23478190" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23478190</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.cameron.2011.486">Cameron JM, Janer A, Levandovskiy V, Mackay N, Rouault TA, Tong WH, Oglivie I, Shoubridge EA, Robinson BH. Mutations in iron-sulfur cluster scaffold genes NFU1 and BOLA3 cause a fatal deficiency of multiple respiratory chain and 2-oxoacid dehydrogenase enzymes. <span><span class="ref-journal">Am J Hum Genet. </span>2011;<span class="ref-vol">89</span>:486–95.</span> [<a href="/pmc/articles/PMC3188835/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3188835</span></a>] [<a href="/pubmed/21944046" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21944046</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.cameron.2006.1542">Cameron JM, Levandovskiy V, Mackay N, Raiman J, Renaud DL, Clarke JT, Feigenbaum A, Elpeleg O, Robinson BH. Novel mutations in dihydrolipoamide dehydrogenase deficiency in two cousins with borderline-normal PDH complex activity. <span><span class="ref-journal">Am J Med Genet A. </span>2006;<span class="ref-vol">140</span>:1542–52.</span> [<a href="/pubmed/16770810" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16770810</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.cerna.2001.1319">Cerna L, Wenchich L, Hansikov&#x000e1; H, Kmoch S, Peskova K, Chrastina P, Brynda J, Zeman J. Novel mutations in a boy with dihydrolipoamide dehydrogenase deficiency. <span><span class="ref-journal">Med Sci Monit. </span>2001;<span class="ref-vol">7</span>:1319–25.</span> [<a href="/pubmed/11687750" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11687750</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.chuang.2014">Chuang DT, Shih VE, Max Wynn RR. Maple syrup urine disease (branched-chain ketoaciduria). In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <em>The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</em> Chap 87. New York, NY: McGraw-Hill. 2014.</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.craigen.1996.69">Craigen WJ. Leigh disease with deficiency of lipoamide dehydrogenase: treatment failure with dichloroacetate. <span><span class="ref-journal">Pediatr Neurol. </span>1996;<span class="ref-vol">14</span>:69–71.</span> [<a href="/pubmed/8652022" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8652022</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.elpeleg.1990.709">Elpeleg ON, Christensen E, Hurvitz H, Branski D. Recurrent, familial Reye-like syndrome with a new complex amino and organic aciduria. <span><span class="ref-journal">Eur J Pediatr. </span>1990;<span class="ref-vol">149</span>:709–12.</span> [<a href="/pubmed/2120061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2120061</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.elpeleg.1995.72">Elpeleg ON, Ruitenbeek W, Jakobs C, Barash V, De Vivo DC, Amir N. Congenital lacticacidemia caused by lipoamide dehydrogenase deficiency with favorable outcome. <span><span class="ref-journal">J Pediatr. </span>1995;<span class="ref-vol">126</span>:72–4.</span> [<a href="/pubmed/7815230" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7815230</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.elpeleg.1997a.238">Elpeleg ON, Saada AB, Shaag A, Glustein JZ, Ruitenbeek W, Tein I, Halevy J. Lipoamide dehydrogenase deficiency: a new cause for recurrent myoglobinuria. <span><span class="ref-journal">Muscle Nerve. </span>1997a;<span class="ref-vol">20</span>:238–40.</span> [<a href="/pubmed/9040667" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9040667</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.elpeleg.1997b.256">Elpeleg ON, Shaag A, Glustein JZ, Anikster Y, Joseph A, Saada A. Lipoamide dehydrogenase deficiency in Ashkenazi Jews: an insertion mutation in the mitochondrial leader sequence. <span><span class="ref-journal">Hum Mutat. </span>1997b;<span class="ref-vol">10</span>:256–7.</span> [<a href="/pubmed/9298831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9298831</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.grafakou.2003.714">Grafakou O, Oexle K, van den Heuvel L, Smeets R, Trijbels F, Goebel HH, Bosshard N, Superti-Furga A, Steinmann B, Smeitink J. Leigh syndrome due to compound heterozygosity of dihydrolipoamide dehydrogenase gene mutations. Description of the first E3 splice site mutation. <span><span class="ref-journal">Eur J Pediatr. </span>2003;<span class="ref-vol">162</span>:714–8.</span> [<a href="/pubmed/12925875" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12925875</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.guffon.1993.821">Guffon N, Lopez-Mediavilla C, Dumoulin R, Mousson B, Godinot C, Carrier H, Collombet JM, Divry P, Mathieu M, Guibaud P. 2-Ketoglutarate dehydrogenase deficiency, a rare cause of primary hyperlactataemia: report of a new case. <span><span class="ref-journal">J Inherit Metab Dis. </span>1993;<span class="ref-vol">16</span>:821–30.</span> [<a href="/pubmed/8295396" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8295396</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.haack.2013.55">Haack TB, Rolinski B, Haberberger B, Zimmermann F, Schum J, Strecker V, Graf E, Athing U, Hoppen T, Wittig I, Sperl W, Freisinger P, Mayr JA, Strom TM, Meitinger T, Prokisch H. Homozygous missense mutation in BOLA3 causes multiple mitochondrial dysfunctions syndrome in two siblings. <span><span class="ref-journal">J Inherit Metab Dis. </span>2013;<span class="ref-vol">36</span>:55–62.</span> [<a href="/pubmed/22562699" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22562699</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.haviv.2014.243">Haviv R, Zeharia A, Belaiche C, Haimi Cohen Y, Saada A. Elevated plasma citrulline: look for dihydrolipoamide dehydrogenase deficiency. <span><span class="ref-journal">Eur J Pediatr. </span>2014;<span class="ref-vol">173</span>:243–5.</span> [<a href="/pubmed/23995961" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23995961</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.hoffmann.2002">Hoffmann GF, Feyh P. Organic acid analysis. In: Blau N, Duran M, Blaskovics ME, Gibson KM, eds. <em>Physician&#x02019;s Guide to the Laboratory Diagnosis of Metabolic Diseases</em>. 2 ed. Berlin, Germany: Springer; 2002:27-44.</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.hong.1996.1925">Hong YS, Kerr DS, Craigen WJ, Tan J, Pan Y, Lusk M, Patel MS. Identification of two mutations in a compound heterozygous child with dihydrolipoamide dehydrogenase deficiency. <span><span class="ref-journal">Hum Mol Genet. </span>1996;<span class="ref-vol">5</span>:1925–30.</span> [<a href="/pubmed/8968745" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8968745</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.hong.1997.160">Hong YS, Kerr DS, Liu TC, Lusk M, Powell BR, Patel MS. Deficiency of dihydrolipoamide dehydrogenase due to two mutant alleles (E340K and G101del). Analysis of a family and prenatal testing. <span><span class="ref-journal">Biochim Biophys Acta. </span>1997;<span class="ref-vol">1362</span>:160–8.</span> [<a href="/pubmed/9540846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9540846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.hong.2003.816">Hong YS, Korman SH, Lee J, Ghoshal P, Wu Q, Barash V, Kang S, Oh S, Kwon M, Gutman A, Rachmel A, Patel MS. Identification of a common mutation (Gly194Cys) in both Arab Moslem and Ashkenazi Jewish patients with dihydrolipoamide dehydrogenase (E3) deficiency: possible beneficial effect of vitamin therapy. <span><span class="ref-journal">J Inherit Metab Dis. </span>2003;<span class="ref-vol">26</span>:816–8.</span> [<a href="/pubmed/14765544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14765544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.kohlsch_tter.1982.32">Kohlsch&#x000fc;tter A, Behbehani A, Langenbeck U, Albani M, Heidemann P, Hoffmann G, Kleineke J, Lehnert W, Wendel U. A familial progressive neurodegenerative disease with 2-oxoglutaric aciduria. <span><span class="ref-journal">Eur J Pediatr. </span>1982;<span class="ref-vol">138</span>:32–7.</span> [<a href="/pubmed/7075624" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7075624</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.kuhara.1983.133">Kuhara T, Shinka T, Inoue Y, Matsumoto M, Yoshino M, Sakaguchi Y, Matsumoto I. Studies of urinary organic acid profiles of a patient with dihydrolipoyl dehydrogenase deficiency. <span><span class="ref-journal">Clin Chim Acta. </span>1983;<span class="ref-vol">133</span>:133–40.</span> [<a href="/pubmed/6688766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6688766</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.liu.1993.5186">Liu TC, Kim H, Arizmendi C, Kitano A, Patel MS. Identification of two missense mutations in a dihydrolipoamide dehydrogenase-deficient patient. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>1993;<span class="ref-vol">90</span>:5186–90.</span> [<a href="/pmc/articles/PMC46680/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC46680</span></a>] [<a href="/pubmed/8506365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8506365</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.matalon.1984.65">Matalon R, Stumpf DA, Michals K, Hart RD, Parks JK, Goodman SI. Lipoamide dehydrogenase deficiency with primary lactic acidosis: favorable response to treatment with oral lipoic acid. <span><span class="ref-journal">J Pediatr. </span>1984;<span class="ref-vol">104</span>:65–9.</span> [<a href="/pubmed/6418873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6418873</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.mayr.2011.792">Mayr JA, Zimmermann FA, Fauth C, Bergheim C, Meierhofer D, Radmayr D, Zschocke J, Koch J, Sperl W. Lipoic acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. <span><span class="ref-journal">Am J Hum Genet. </span>2011;<span class="ref-vol">89</span>:792–7.</span> [<a href="/pmc/articles/PMC3234378/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3234378</span></a>] [<a href="/pubmed/22152680" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22152680</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.millington.2002">Millington DS. Tandem mass spectrometry in clinical diagnosis. In: Blau N, Duran M, Blaskovics ME, Gibson KM, eds. <em>Physician&#x02019;s Guide to the Laboratory Diagnosis of Metabolic Diseases</em>. 2 ed. Berlin: Springer; 2002:57-75.</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.munnich.1982.167">Munnich A, Saudubray JM, Taylor J, Charpentier C, Marsac C, Rocchiccioli F, Amedee-Manesme O, Coude FX, Frezal J, Robinson BH. Congenital lactic acidosis, alpha-ketoglutaric aciduria and variant form of maple syrup urine disease due to a single enzyme defect: dihydrolipoyl dehydrogenase deficiency. <span><span class="ref-journal">Acta Paediatr Scand. </span>1982;<span class="ref-vol">71</span>:167–71.</span> [<a href="/pubmed/6897145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6897145</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.navarrosastre.2011.656">Navarro-Sastre A, Tort F, Stehling O, Uzarska MA, Arranz JA, Del Toro M, Labayru MT, Landa J, Font A, Garcia-Villoria J, Merinero B, Ugarte M, Gutierrez-Solana LG, Campistol J, Garcia-Cazorla A, Vaquerizo J, Riudor E, Briones P, Elpeleg O, Ribes A, Lill R. A fatal mitochondrial disease is associated with defective NFU1 function in the maturation of a subset of mitochondrial Fe-S proteins. <span><span class="ref-journal">Am J Hum Genet. </span>2011;<span class="ref-vol">89</span>:656–67.</span> [<a href="/pmc/articles/PMC3213398/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3213398</span></a>] [<a href="/pubmed/22077971" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22077971</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.odi_vre.2005.323">Odi&#x000e8;vre MH, Chretien D, Munnich A, Robinson BH, Dumoulin R, Masmoudi S, Kadhom N, R&#x000f6;tig A, Rustin P, Bonnefont JP. A novel mutation in the dihydrolipoamide dehydrogenase E3 subunit gene (DLD) resulting in an atypical form of alpha-ketoglutarate dehydrogenase deficiency. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">25</span>:323–4.</span> [<a href="/pubmed/15712224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15712224</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.patel.2012.385">Patel KP, O'Brien TW, Subramony SH, Shuster J, Stacpoole PW. The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">106</span>:385–94.</span> [<a href="/pmc/articles/PMC4003492/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4003492</span></a>] [<a href="/pubmed/22896851" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22896851</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.quinonez.2013.67">Quinonez SC, Leber SM, Martin DM, Thoene JG, Bedoyan JK. Leigh syndrome in a girl with a novel DLD mutation causing E3 deficiency. <span><span class="ref-journal">Pediatr Neurol. </span>2013;<span class="ref-vol">48</span>:67–72.</span> [<a href="/pmc/articles/PMC4535688/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4535688</span></a>] [<a href="/pubmed/23290025" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23290025</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.quintana.2010.s315">Quintana E, Pineda M, Font A, Vilaseca MA, Tort F, Ribes A, Briones P. Dihydrolipoamide dehydrogenase (DLD) deficiency in a Spanish patient with myopathic presentation due to a new mutation in the interface domain. <span><span class="ref-journal">J Inherit Metab Dis. </span>2010;<span class="ref-vol">33</span> Suppl 3:S315–9.</span> [<a href="/pubmed/20652410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20652410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.robinson.1981.35">Robinson BH, Taylor J, Kahler SG, Kirkman HN. Lactic acidemia, neurologic deterioration and carbohydrate dependence in a girl with dihydrolipoyl dehydrogenase deficiency. <span><span class="ref-journal">Eur J Pediatr. </span>1981;<span class="ref-vol">136</span>:35–9.</span> [<a href="/pubmed/6894281" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6894281</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.robinson.1977.1198">Robinson BH, Taylor J, Sherwood WG, Fraser D. Deficiency of dihydrolipoyl dehydrogenase (a component of the pyruvate and alpha-ketoglutarate dehydrogenase complexes): a cause of congenital chronic lactic acidosis in infancy. <span><span class="ref-journal">Pediatr Res. </span>1977;<span class="ref-vol">11</span>:1198–202.</span> [<a href="/pubmed/413089" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 413089</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.sansaricq.2006.203">Sansaricq C, Pardo S, Balwani M, Grace M, Raymond K. Biochemical and molecular diagnosis of lipoamide dehydrogenase deficiency in a North American Ashkenazi Jewish family. <span><span class="ref-journal">J Inherit Metab Dis. </span>2006;<span class="ref-vol">29</span>:203–4.</span> [<a href="/pubmed/16601893" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16601893</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.schadewaldt.1999.1734">Schadewaldt P, Bodner-Leidecker A, Hammen HW, Wendel U. Significance of L-alloisoleucine in plasma for diagnosis of maple syrup urine disease. <span><span class="ref-journal">Clin Chem. </span>1999;<span class="ref-vol">45</span>:1734–40.</span> [<a href="/pubmed/10508118" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10508118</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.schaefer.1999.910">Schaefer F, Straube E, Oh J, Mehls O, Mayatepek E. Dialysis in neonates with inborn errors of metabolism. <span><span class="ref-journal">Nephrol Dial Transplant. </span>1999;<span class="ref-vol">14</span>:910–8.</span> [<a href="/pubmed/10328469" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10328469</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.scott.2010.1240">Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ. Kornreich. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. <span><span class="ref-journal">Hum Mutat. </span>2010;<span class="ref-vol">31</span>:1240–50.</span> [<a href="/pmc/articles/PMC2970726/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2970726</span></a>] [<a href="/pubmed/20672374" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20672374</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.shaag.1999.177">Shaag A, Saada A, Berger I, Mandel H, Joseph A, Feigenbaum A, Elpeleg ON. Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">82</span>:177–82.</span> [<a href="/pubmed/9934985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9934985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.shany.1999.163">Shany E, Saada A, Landau D, Shaag A, Hershkovitz E, Elpeleg ON. Lipoamide dehydrogenase deficiency due to a novel mutation in the interface domain. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>1999;<span class="ref-vol">262</span>:163–6.</span> [<a href="/pubmed/10448086" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10448086</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.shih.2002">Shih VE. Amino acid analysis. In: Blau N, Duran M, Blaskovics ME, Gibson KM, eds. <em>Physician&#x02019;s Guide to the Laboratory Diagnosis of Metabolic Diseases</em>. 2 ed. Berlin, Germany: Springer; 2002:11-26.</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.soreze.2013.192">Soreze Y, Boutron A, Habarou F, Barnerias C, Nonnenmacher L, Delpech H, Mamoune A, Chr&#x000e9;tien D, Hubert L, Bole-Feysot C, Nitschke P, Correia I, Sardet C, Boddaert N, Hamel Y, Delahodde A, Ottolenghi C, de Lonlay P. Mutations in human lipoyltransferase gene LIPT1 cause a Leigh disease with secondary deficiency for pyruvate and alpha-ketoglutarate dehydrogenase. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2013;<span class="ref-vol">8</span>:192.</span> [<a href="/pmc/articles/PMC3905285/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3905285</span></a>] [<a href="/pubmed/24341803" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24341803</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.stacpoole.2008.e1223">Stacpoole PW, Gilbert LR, Neiberger RE, Carney PR, Valenstein E, Theriaque DW, Shuster JJ. Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. <span><span class="ref-journal">Pediatrics. </span>2008;2008;<span class="ref-vol">121</span>:e1223–8.</span> [<a href="/pmc/articles/PMC3777225/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3777225</span></a>] [<a href="/pubmed/18411236" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18411236</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.tort.2014.1907">Tort F, Ferrer-Cort&#x000e8;s X, Thi&#x000f3; M, Navarro-Sastre A, Matalonga L, Quintana E, Bujan N, Arias A, Garc&#x000ed;a-Villoria J, Acquaviva C, Vianey-Saban C, Artuch R, Garc&#x000ed;a-Cazorla A, Briones P, Ribes A. Mutations in the lipoyltransferase LIPT1 gene cause a fatal disease associated with a specific lipoylation defect of the 2-ketoacid dehydrogenase complexes. <span><span class="ref-journal">Hum Mol Genet. </span>2014;<span class="ref-vol">23</span>:1907–15.</span> [<a href="/pubmed/24256811" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24256811</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="dld-def.REF.vaubel.2011.40232">Vaubel RA, Rustin P, Isaya G. Mutations in the dimer interface of dihydrolipoamide dehydrogenase promote site-specific oxidative damages in yeast and human cells. <span><span class="ref-journal">J Biol Chem. </span>2011;<span class="ref-vol">286</span>:40232–45.</span> [<a href="/pmc/articles/PMC3220568/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3220568</span></a>] [<a href="/pubmed/21930696" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21930696</span></a>]</div></li></ul></div></div><div id="dld-def.Chapter_Notes"><h2 id="_dld-def_Chapter_Notes_">Chapter Notes</h2><div id="dld-def.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>17 July 2014 (me) Review posted live</div></li><li class="half_rhythm"><div>21 February 2014 (sq) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK220444</span><span class="label">PMID: <a href="/pubmed/25032271" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">25032271</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/diastrophic-d/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/dcm-ov/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK220444&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK220444/?report=reader">PubReader</a></li><li><a href="/books/NBK220444/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK220444" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK220444" style="display:none" title="Cite this Page"><div class="bk_tt">Quinonez SC, Thoene JG. Dihydrolipoamide Dehydrogenase Deficiency. 2014 Jul 17. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK220444/pdf/Bookshelf_NBK220444.pdf">PDF version of this page</a> (491K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#dld-def.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#dld-def.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#dld-def.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#dld-def.Genetically_Related_Allelic_Diso" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#dld-def.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#dld-def.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#dld-def.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#dld-def.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#dld-def.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#dld-def.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#dld-def.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1738[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">DLD</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=3180580" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=3180580" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=3180580" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=3180580" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301495" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Maple Syrup Urine Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Maple Syrup Urine Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Strauss KA, Puffenberger EG, Morton DH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22593918" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propionic Acidemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propionic Acidemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shchelochkov OA, Carrillo N, Venditti C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21290785" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Argininosuccinate Lyase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Argininosuccinate Lyase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nagamani SCS, Erez A, Lee B. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31536184" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glutaric Acidemia Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glutaric Acidemia Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Larson A, Goodman S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=25032271" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=25032271" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04162f39a66ee2ba16b5e0">Dihydrolipoamide Dehydrogenase Deficiency - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Dihydrolipoamide Dehydrogenase Deficiency - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:08:47-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C0629E04065F10000000006AA025E&amp;ncbi_session=CE8C0629E04162F1_1706SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK220444%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK220444&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK220444/&amp;ncbi_pagename=Dihydrolipoamide Dehydrogenase Deficiency - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C0629E04162F1_1706SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>